The Riddle Institute for Regenerative Medicine (RIRM) is structured in such a way as to allow individual investors to invest in specific projects. Each project will have its own associated limited liability company (LLC). RIRM is an umbrella company currently encompassing eight separate project-driven companies and retains 50% ownership interest in each. To further pursue investment opportunities, please contact Dr. Riddle. There is currently an investment opportunity opening in pancreas research. The Riddle Institute is working to engineer insulin-producing pancreatic tissue using stem cells and pancreatic tissue bioscaffolds for transplant that would be a long term treatment for type 1 diabetes.